In March of 2017, Immune Therapeutics, Inc. announced that it signed a Memorandum of Understanding (“MOU”) for distribution of its patented Lodonal™ in Kenya.
Immune Therapeutics Announces
NAFDAC Approval for Marketing & Distribution of Lodonal™
Immune Therapeutics Emerges as a Key Player in Immunotherapy Field
research & immunology
Discover more about
our research and technology
research and investigation
Investing in a better and healthier
world today to see it tomorrow
CAR-T cell therapy involves engineering cancer patients’ own immune cells to recognize and attack cancer tumors
Lodonal Nigeria Study
Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has recently approved Immune Therapeutics, Inc. patented Lodonal™ as an over the counter, non-toxic adjunct therapy in the treatment of HIV/AIDS and immune system regulator.
LDN Doctor Locator
Locate Immune Therapeutics, Inc. formulated LDN in the United States.
Read about the additional US and international studies using LDN and MENK
In April of 2016, Immune Therapeutics, Inc. entered into a binding letter of intent with Super T-Cell Cancer Company, a newly formed Chinese corporation, for the acquisition of Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, Immuno-Oncology patents (pending), manufacturing technology, and clinical data.
In January 2015, The Jack Brewer Foundation (JBF Worldwide)(insert link) and Immune Therapeutics, Inc. announced first-of-its-kind donation program to improve access to treatment to prevent cervical cancer that until now has been unavailable to the women of Malawi, Africa.
Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has recently approved its Immune Therapeutics, Inc. patented Lodonal™ as an over the counter, non-toxic adjunct therapy in the treatment of HIV/AIDS and immune system regulator.
In October 2012, the Company and Hubei Qianjiang Pharmaceutical Co., Ltd., a Chinese pharmaceutical company, announced an agreement to co-develop new cancer drugs based on Immune Therapeutics’ patents involving MENK
ORLANDO, Florida, May 22, 2017 – Immune Therapeutics, Inc. (OTCQB: IMUN), a specialty pharmaceutical company focused on developing and commercializing its novel patented, affordable, non-toxic therapy for the treatment of cancer, HIV, autoimmune disease, and other inflammatory conditions, today announced that it has received NAFDAC (National Agency for Food and Drug Administration and Control) approval to market and distribute LodonalTM, the Company’s breakthrough treatment for HIV/AIDS in Nigeria. The Company and its strategic partners plan to immediately initiate sales activities of this first-to-market opportunity.
ORLANDO, Fla., April 25, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM its proprietary formulation of lower-dose naltrexone, today announced it has submitted its New Drug Application (NDA) to the Pharmacy and Poison Board (PPB) in Kenya for Lodonal for the treatment of patients with HIV and cancer, both as a standalone treatment as well as an adjunct treatment, and as an immunomodulator.
LDN holds great promise for the millions of people worldwide with autoimmune diseases or central nervous system disorders or who face a deadly cancer. It could prove to be the first low-cost, easy to administer, and side-effect-free therapy for Cancer, HIV/AIDS, MS and Crohn’s disease
Providing safe, effective and innovative pharmaceutical products that contribute to the well-being and health of the people since 1972